Blakely’s Story

Giovanni’s Story

Ryan’s Story

Ed’s Story

Open Letter by Bryan Melchor

Bryan Melchor

Bryan & Nikkolette Melchor with Edie Zusman, MD, Neurosurgeon, Medical Director NorthBay Center for Neuroscience

Stroke Awareness Month
The Day the Music Died

Time will forever be marked by life before August 2, 2015 and life after this day when I was joyfully leading my church band in songs of praise – feeling so grateful and uplifted by the gospel music I was a part of. Then the music stopped. I felt sleepy. My speech was slurred. I was having a massive hemorrhagic stroke, and I was only 30 years old.  Read the full letter. (pdf)

WHO IS NICO?

NICO Corporation, formed in October 2007, is dedicated to developing technology for the field of corridor surgery, including Cranial, ENT, Spinal and Otolaryngology where access to the surgical site is limited. Our technology and products are designed to progress corridor surgery by creating instruments that allow for access through smaller openings and resection of soft tissue abnormalities.

NICO develops its technology by the following core guiding principles:

  • Develop technology that addresses the unmet needs of the patient.
  • Develop technology that “levels the playing field” for the clinician so that as higher levels of procedural difficulty are encountered, the ability to address clinical outcomes remain reproducible and predictable.
  • Develop technology that addresses economic outcomes for the health care provider.

Worldwide, NICO Corporation currently has more than 250 patents and patents pending.

WHAT IS BRAINPATH?

BP familyThe NICO BrainPath is the newest product family in the NICO portfolio. It provides for access and visualization of lesions in the subcortical space of the brain. The BrainPath dramatically changes how surgeons can move through the natural folds and delicate fibers of the brain. The BrainPath’s obturator is uniquely designed with a minimally disruptive tip that minimizes tissue damage by displacing tissues of the brain during advancement to the targeted abnormality. The sheath remains in the brain after the obturator is removed to serve as a protective portal for surgeons to easily maintain access to the surgical site.

                    

Learn More

BRAINPATH and INTRACEREBRAL HEMORRHAGE

brain-image-2
Approximately 120,000 hemorrhagic strokes occur each year in the United States. This accounts for 10 – 15% of all stroke cases. Unfortunately, almost 80% of patients are left physically disabled after their stroke episode. Your doctor may recommend using the BrainPath for evacuation of the clot causing your intracerebral hemorrhage.

In February 2015, the National Stroke Association called the BrainPath approach a “New Breakthrough in Hemorrhagic Stroke Treatment” in their publication, StrokeSmart.

Learn More Patient Info on Intracerebral Hemorrhage

Related News Stories

Hemorrhagic Stroke Story Clevland Ohio

Brainpath sugery patient in the news
Hemorrhagic Advances in StrokeSmart News

home-page_news-from-strokesmartxxxhome-page_news-from-aha_bxxxx strokesmart image 3

WHAT IS MYRIAD?

The NICO Myriad system consists of the console, handpieces and ancillary products. All NICO Myriad handpieces have a side mouth cutting and aspiration aperture located .6mm from the blunt dissector end that allows for tissue removal without injury to adjacent critical structures.1 The NICO Myriad handpieces are available in 11, 13, 15, 17 and 19 gauges and a variety of lengths.

 

                  

Learn More

TISSUE PRESERVATION SYSTEM

Tissue Collector w new filter elementThe NICO Myriad and Tissue Preservation System collect tissue in a sterile closed system, minimizing its exposure to air during the surgical procedure. The tissue filter element has a “clamshell” design for easily removing the collected tissue in the lab. NICO has designed this preservation system to address the needs of pathology and oncology for collection of tissue.

 

          

Learn More

WHY IS TISSUE COLLECTION IMPORTANT?

Tissue Collector w new filter elementMolecular Technology/Genomic Testing has evolved to the extent that some cancers can be matched to specific chemotherapies that have been shown to respond to certain gene expression patterns. Being able to obtain accurate gene expression patterns of the cancer cells removed from a patient may allow for the potential for personalized chemotherapy treatments.

FREQUENTLY ASKED QUESTIONS

Click to View FAQ's